News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GTx, Inc. (GTXI) Announces Late Breaker Presentation on Results From the Two Phase 3 POWER Trials of Enobosarm, a Selective Androgen Receptor Modulator (SARM), for the Prevention and Treatment of Muscle Wasting in NSCLC Patients During 2013 European Cancer Congress


9/24/2013 10:01:36 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) announced today that top line results from the two Phase 3 trials (POWER1 and POWER2) on the effects of enobosarm for the prevention and treatment of muscle wasting in non-small cell lung cancer patients will be presented on September 28, 2013, at the European Cancer Congress 2013 (September 27-October 1, 2013) in Amsterdam.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
GTx, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES